Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock increase of over 6% following the announcement of its registration application for a new treatment for myopia in children, which has been accepted for review by the Australian Therapeutic Goods Administration [1] Group 1: Company Announcement - On January 13, Zhaoke Ophthalmology-B announced that its registration application for the atropine sulfate eye drops (0.01% dosage, product code: NVK002) aimed at treating progressive myopia in children has been accepted for evaluation by the Australian Therapeutic Goods Administration [1] - The Therapeutic Goods Administration has officially informed the company that the application has passed the preliminary review and will undergo further evaluation [1] - The application is based on supportive results from the company's Phase III clinical trials [1] Group 2: Product Details - Atropine sulfate eye drops (NVK002) are a novel experimental topical ophthalmic solution designed to control the progression of myopia in children and adolescents [1] - The formulation of atropine sulfate eye drops (NVK002) is patented and successfully addresses the instability of low-concentration atropine, with intellectual property protection globally [1] - The product is preservative-free and is expected to have a shelf life of over 24 months [1]

Core Viewpoint - The company Zhaoke Ophthalmology-B (06622) has had its application for the registration of atropine sulfate eye drops accepted by the Australian Therapeutic Goods Administration, aimed at treating myopia progression in children [1] Group 1: Application Details - The application for the 0.01% atropine sulfate eye drops (product code: NVK002) was officially acknowledged by the Therapeutic Goods Administration on January 5, 2026, and has passed the preliminary review stage [1] - The application is supported by results from the company's Phase III clinical trials [1] Group 2: Product Information - Atropine sulfate eye drops (NVK002) are an experimental new topical ophthalmic solution designed to control myopia progression in children and adolescents [1] - The product features a patented formulation that successfully addresses the instability of low-concentration atropine, with global intellectual property protection [1] - The eye drops are preservative-free and are expected to have a shelf life of over 24 months [1] Group 3: Market Position - According to Zhi Shi Consulting, NVK002 is currently one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient demographic of children and adolescents aged 3 to 17 [1]

本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，於2026年1月5日，澳 洲Therapeutic Goods Administration（治 療 用 品 管 理 局）（「治療用品局」）已 受 理 評 核 本 公 司 就 其 用 於 治 療 兒 童 近 視 加 深 的 硫 酸 阿 托 品 滴 眼 液（0.01%劑 量，產 品 代 碼：NVK002）提 出 的 註 冊 申 請。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 （股份代號：6622） 澳 洲THERAPEUTIC GOODS ADMINISTRATION（治 療 用 品 管 理 局） 受理評核 硫酸阿托品滴 ...

Core Viewpoint - The stock price of Zhaoke Ophthalmology (06622) experienced significant volatility after reaching a peak of HKD 4.60 on August 18, 2023, marking a year-to-date increase of 283.33%. However, the stock has since entered a downward trend, with a cumulative decline of 30% over the following two and a half months, despite a recent milestone in the approval process for its key product, NVK002 [1][4][6]. Group 1: Stock Performance - Zhaoke Ophthalmology's stock price surged to a peak of HKD 4.60, reflecting a year-to-date increase of 283.33% [1] - Following the peak, the stock entered a downward trend characterized by "nine consecutive declines" and "ten consecutive declines," resulting in a cumulative drop of 30% [1] - On October 22, the stock saw a brief increase of 3.58% after the ANDA application for NVK002 was fully approved, but this gain was quickly reversed with a subsequent drop of 4.72% the following day [2][4] Group 2: Financial Performance - For the first half of 2023, Zhaoke Ophthalmology reported revenue of HKD 15.803 million, a year-on-year decline of 68.25%, and a net loss of HKD 117 million, an increase of 53.85% compared to the previous year [4] - The significant revenue drop was primarily due to a one-time licensing income of HKD 33.5 million in the previous year, which inflated the revenue base [4] - After adjusting for this one-time income, the product revenue for the current period was approximately HKD 15.1 million, showing only a slight decline from HKD 15.6 million in the same period last year [4] Group 3: Product Development and Market Potential - Zhaoke Ophthalmology's NVK002, a low-concentration atropine eye drop, has made significant progress, with its ANDA application accepted by the National Medical Products Administration of China [4][5] - The company is currently the only one in China with two concentrations of atropine eye drops under regulatory review, indicating a strong competitive position [5] - The potential market for myopia control in China is substantial, with approximately 700 million myopic patients, including 163 million children and adolescents who could benefit from NVK002 [5] - According to estimates, the myopia prevention market could reach HKD 210 billion by 2030, with a compound annual growth rate of approximately 13.7% [5] Group 4: Market Sentiment and Future Outlook - Following a significant price increase, the stock has shown signs of consolidation, with a current PB ratio of 0.92, well below the industry average of 3.15 [3] - The stock has experienced a "price flat, volume shrinking" phenomenon, indicating a potential stabilization at lower price levels [15] - Recent trading activity suggests that the stock may be nearing a bottom, with a potential for upward momentum if trading volume increases [15]

Core Viewpoint - The stock price of Zhaoke Ophthalmology (06622) experienced significant volatility after reaching a peak of HKD 4.60 on August 18, 2023, marking a year-to-date increase of 283.33%. However, the stock has since declined by approximately 30% over the following two and a half months, despite a recent milestone in the approval process for its key product, NVK002 [1][4][6]. Group 1: Stock Performance - Zhaoke Ophthalmology's stock price surged to a high of HKD 4.60, reflecting a year-to-date increase of 283.33% [1] - Following the peak, the stock entered a downward trend, experiencing a "slow knife" decline with a cumulative drop of 30% over two and a half months [1][2] - On October 22, the stock saw a brief increase of 3.58% after the ANDA application for NVK002 was fully approved, but this gain was quickly reversed with a subsequent drop of 4.72% the next day [2][6] Group 2: Financial Performance - For the first half of 2025, Zhaoke Ophthalmology reported revenue of HKD 15.803 million, a decline of 68.25% year-on-year, and a net loss of HKD 117 million, widening by 53.85% [4] - The revenue drop was primarily due to a one-time licensing income of HKD 33.5 million in the previous year, which inflated the revenue base [4] - Excluding this factor, product revenue was approximately HKD 15.1 million, showing only a slight decline from HKD 15.6 million in the same period last year [4] Group 3: Product Development - Zhaoke Ophthalmology's NVK002, a low-concentration atropine eye drop for myopia control, has made significant progress, with its ANDA application accepted by the National Medical Products Administration [4][5] - The company is the only one in China with two concentrations of atropine eye drops under regulatory review, indicating a strong market position [5] - The global myopia control market is projected to reach HKD 210 billion by 2030, with a compound annual growth rate of approximately 13.7% [5] Group 4: Market Dynamics - The current PB valuation of Zhaoke Ophthalmology is 0.92, significantly lower than the industry average of 3.15, indicating potential undervaluation [3] - The market for low-concentration atropine eye drops is currently limited, with only one competitor, suggesting a favorable competitive landscape for NVK002 [5] - Recent trading patterns indicate a consolidation phase, with a significant portion of the stock's average cost now at HKD 3.24, suggesting improved control by major investors [12][15]

Group 1 - The core viewpoint of the article highlights that Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 7% and currently trading at 4.27 HKD with a transaction volume of 10.87 million HKD [1] - Zhaoke Ophthalmology has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals, a leading pharmaceutical company in Indonesia, for its core product, atropine sulfate eye drops (NVK002), aimed at slowing the progression of myopia in children and adolescents [1] - Under the agreement, Zhaoke Ophthalmology grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia, which includes an upfront payment and potential milestone payments based on certain achievements [1] Group 2 - Earlier this year, Zhaoke Ophthalmology's new drug application for a 0.01% dosage of atropine sulfate eye drops and a 0.02% dosage has been accepted by the National Medical Products Administration of China and is currently under review [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, attributed to a distribution and supply agreement with Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for its core product, atropine eye drops aimed at slowing myopia progression in children and adolescents [1] Group 1: Company Developments - Zhaoke Ophthalmology has signed an exclusive distribution and supply agreement with PT Ferron for the import, promotion, distribution, marketing, and sales of its atropine eye drops in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] - Earlier this year, Zhaoke Ophthalmology's applications for the 0.01% and 0.02% formulations of atropine eye drops have been accepted by the National Medical Products Administration of China and are currently under review [1] Group 2: Market Performance - The stock price of Zhaoke Ophthalmology has increased by over 7%, with a current rise of 6.48%, trading at HKD 4.27, and a transaction volume of HKD 10.8763 million [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, attributed to a new distribution agreement with PT Ferron Par Pharmaceuticals for its core product, a atropine eye drop aimed at slowing myopia progression in children and adolescents [1] Company Summary - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron Par Pharmaceuticals, granting exclusive rights for importing, promoting, distributing, marketing, and selling its atropine eye drop product in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on certain achievements related to the product [1] - Earlier this year, Zhaoke Ophthalmology's applications for a simplified new drug for 0.01% and 0.02% concentrations of the atropine eye drop have been accepted by the National Medical Products Administration of China and are currently under review [1] Market Reaction - Following the announcement, Zhaoke Ophthalmology's stock price increased by over 7%, with a current price of 4.27 HKD and a trading volume of 10.8763 million HKD [1]